| | |
Page
Number |
| |||
Notice of Annual Meeting of Stockholders | | | | | | | |
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 10 | | | |
| | | | 13 | | | |
Proposals to be Voted Upon | | | | | | | |
| | | | 14 | | | |
| | | | 19 | | | |
| | | | 20 | | |
Name
|
| |
Age
|
| |
Title
|
|
Steven H. Rouhandeh | | |
62
|
| | Chairman of the Board and Executive Chairman* | |
João Siffert, M.D. | | |
55
|
| | Chief Executive Officer and Director** | |
Timothy J. Miller, Ph.D. | | |
47
|
| | President and Chief Scientific Officer | |
Christine Berni Silverstein | | |
36
|
| | Chief Financial Officer*** | |
Edward Carr | | |
49
|
| | Vice President and Chief Accounting Officer† | |
Richard Van Duyne | | |
65
|
| | Director | |
Mark J. Alvino | | |
51
|
| | Director | |
Stephen B. Howell, M.D. | | |
74
|
| | Director | |
Todd Wider, M.D. | | |
54
|
| | Director | |
Stefano Buono | | |
52
|
| | Director | |
Name
|
| |
Fees Earned or
Paid in Cash ($) |
| |
Option Awards
($)(1) |
| |
Total
($) |
| |||||||||
Mark J. Alvino
|
| | | $ | 45,000 | | | | | $ | —(2) | | | | | $ | 45,000 | | |
Stefano Buono
|
| | | | 33,750 | | | | | | 377,808(3) | | | | | | 411,558 | | |
Stephen B. Howell, M.D.
|
| | | | 45,000 | | | | | | —(4) | | | | | | 45,000 | | |
Richard Van Duyne
|
| | | | 33,750 | | | | | | 377,808(5) | | | | | | 411,558 | | |
Todd Wider, M.D.
|
| | | | 45,000 | | | | | | 538,737(6) | | | | | | 583,737 | | |
Plan Category
|
| |
Number of
securities to be issued upon exercise of outstanding options, warrants and rights (a) |
| |
Weighted-average
exercise price of outstanding options, warrants and rights (b) |
| |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) |
| |||||||||
Equity compensation plans approved by security holders:
|
| | | | | | | | | | | | | | | | | | |
2015 Equity Incentive Plan
|
| | | | 5,525,405 | | | | | $ | 8.08 | | | | | | 2,333,346 | | |
2005 Equity Incentive Plan(1)
|
| | | | 316,400 | | | | | | 14.15 | | | | | | — | | |
Equity compensation plans not approved by security holders
|
| | | | — | | | | | | — | | | | | | — | | |
Total
|
| | | | 5,841,805 | | | | | $ | 8.41 | | | | | | 2,333,346 | | |
|
Name and Address of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership Common Stock(1) |
| |
Percent of
Common Stock(2) |
| ||||||
Steven H. Rouhandeh(3)
|
| | | | 14,600,492 | | | | | | 30.0% | | |
Mark J. Alvino(4)
|
| | | | 292,000 | | | | | | * | | |
Stefano Buono(5)
|
| | | | 30,000 | | | | | | * | | |
Stephen B. Howell, M.D.(6)
|
| | | | 295,195 | | | | | | * | | |
João Siffert, M.D.
|
| | | | — | | | | | | * | | |
Richard Van Duyne(7)
|
| | | | 30,000 | | | | | | * | | |
Todd Wider, M.D.(8)
|
| | | | 455,000 | | | | | | * | | |
Timothy J. Miller, Ph.D.(9)
|
| | | | 1,013,185 | | | | | | 2.1% | | |
Christine Berni Silverstein(10)
|
| | | | 164,063 | | | | | | * | | |
Edward Carr
|
| | | | — | | | | | | * | | |
SCO Capital Partners LLC and Beach Capital LLC(11)
|
| | | | 13,694,659 | | | | | | 28.3% | | |
FMR LLC(12)
|
| | | | 7,191,672 | | | | | | 15.0% | | |
Adage Capital Partners L.P.(13)
|
| | | | 2,600,000 | | | | | | 5.4% | | |
T. Rowe Price(14)
|
| | | | 2,549,555 | | | | | | 5.3% | | |
Wellington Management Group LLP(15)
|
| | | | 4,071,217 | | | | | | 8.5% | | |
All Directors and Executive Officers as a group (consisting of 10 persons)
|
| | | | 16,879,935 | | | | | | 33.6% | | |
Name and Principal Position
|
| |
Year
|
| |
Salary
($) |
| |
Bonus
($) |
| |
Option Awards
($)(1) |
| |
All Other
Compensation ($) |
| |
Total
($) |
| ||||||||||||||||||
Steven H. Rouhandeh
Executive Chairman |
| | | | 2018 | | | | | $ | 515,000 | | | | | $ | 244,625(2) | | | | | $ | — | | | | | $ | 14,925(3) | | | | | $ | 774,550 | | |
| | | 2017 | | | | | $ | 386,000 | | | | | $ | 154,000(4) | | | | | $ | 1,521,000(5) | | | | | $ | — | | | | | $ | 2,061,000 | | | ||
João Siffert, M.D.(6)
Chief Executive Officer, Head of Research & Development and Chief Medical Officer |
| | | | 2018 | | | | | $ | 104,295 | | | | | $ | 45,818(2) | | | | | $ | 1,313,990(7) | | | | | $ | 95,000(8) | | | | | $ | 1,559,103 | | |
Timothy J. Miller, Ph.D.
President and Chief Scientific Officer |
| | | | 2018 | | | | | $ | 433,750 | | | | | $ | 124,920(2) | | | | | $ | — | | | | | $ | 17,325(3) | | | | | $ | 575,995 | | |
| | | 2017 | | | | | $ | 375,000 | | | | | $ | 150,000(4) | | | | | $ | 1,141,000(5) | | | | | $ | — | | | | | $ | 1,666,000 | | | ||
Frank Carsten Thiel, Ph.D.(9)
Former Chief Executive Officer |
| | | | 2018 | | | | | $ | 358,558 | | | | | $ | — | | | | | $ | 3,771,159(10) | | | | | $ | 41,479(11) | | | | | $ | 4,171,196 | | |
| | | | | | | | |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||||||||||||||
Name
|
| |
Grant
Date |
| |
Number of
Securities Underlying Unexercised Options (#) Exercisable |
| |
Number of
Securities Underlying Unexercised Options (#) Unexercisable |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| |
Number of
Shares or Units of Stock That Have Not Vested (#) |
| |
Market Value of
Shares or Units of Stock That Have Not Vested ($)(1) |
| |||||||||||||||||||||
Steven H. Rouhandeh | | | | | 12/14/2017 | | | | | | 30,000 | | | | | | 90,000(2) | | | | | $ | 16.00 | | | | | | 12/14/2027 | | | | | | — | | | | | $ | — | | |
| | | | | 12/13/2016 | | | | | | 100,000 | | | | | | 100,000(2) | | | | | $ | 4.45 | | | | | | 12/13/2026 | | | | | | — | | | | | $ | — | | |
| | | | | 2/11/2016 | | | | | | 141,667 | | | | | | 58,333(2) | | | | | $ | 2.31 | | | | | | 2/11/2026 | | | | | | — | | | | | $ | — | | |
| | | | | 5/11/2015 | | | | | | 125,000 | | | | | | — | | | | | $ | 7.34 | | | | | | 5/11/2025 | | | | | | — | | | | | $ | — | | |
| | | | | 3/7/2014 | | | | | | 80,000 | | | | | | — | | | | | $ | 18.50 | | | | | | 3/7/2024 | | | | | | — | | | | | $ | — | | |
| | | | | 5/11/2015 | | | | | | — | | | | | | — | | | | | $ | — | | | | | | — | | | | | | 375,000(2) | | | | | $ | 2,677,500 | | |
João Siffert, M.D. | | | | | 10/24/2018 | | | | | | — | | | | | | 180,000(3) | | | | | $ | 9.23 | | | | | | 10/24/2028 | | | | | | — | | | | | $ | — | | |
Timothy J. Miller, Ph.D. | | | | | 12/14/2017 | | | | | | 22,500 | | | | | | 67,500(4) | | | | | $ | 16.00 | | | | | | 12/14/2027 | | | | | | — | | | | | $ | — | | |
| | | | | 12/13/2016 | | | | | | 75,000 | | | | | | 75,000(4) | | | | | $ | 4.45 | | | | | | 12/13/2026 | | | | | | — | | | | | $ | — | | |
| | | | | 2/11/2016 | | | | | | 106,250 | | | | | | 43,750(4) | | | | | $ | 2.31 | | | | | | 2/11/2026 | | | | | | — | | | | | $ | — | | |
| | | | | 5/11/2015 | | | | | | 358,333 | | | | | | 41,667(4) | | | | | $ | 7.34 | | | | | | 5/11/2025 | | | | | | — | | | | | $ | — | | |
Frank Carsten Thiel, Ph.D.
|
| | | | | | | | | | — | | | | | | —(5) | | | | | $ | — | | | | | | | | | | | | — | | | | | $ | — | | |
Types of Fees
|
| |
2018
|
| |
2017
|
| ||||||
Audit Fees(1)
|
| | | $ | 230,000 | | | | | $ | 146,000 | | |
Audit-Related Fees(2)
|
| | | $ | 17,000 | | | | | $ | 31,000 | | |
Tax Fees
|
| | | $ | 0 | | | | | $ | 0 | | |
All Other Fees
|
| | | $ | 0 | | | | | $ | 0 | | |
|
☐
FOR ALL NOMINEES
|
| |
NOMINEES:
_________ Mark J. Alvino
_________ Stefano Buono _________ Dr. João Siffert
|
|
|
☐
WITHHOLD AUTHORITY
FOR ALL NOMINEES
|
| | ||
|
☐
FOR ALL EXCEPT
(see instructions below)
|
| | | |
|
2.
Approve, on an advisory basis, the compensation of our named executive officers.
|
| |
FOR
☐ |
| |
AGAINST
☐ |
| |
ABSTAIN
☐ |
|
|
3.
Ratify the appointment of Whitley Penn LLP as our independent registered public accountant for the fiscal year ending December 31, 2019.
|
| |
FOR
☐ |
| |
AGAINST
☐ |
| |
ABSTAIN
☐ |
|